SCHEMBL68260

SCHEMBL68260

Cc1ccc2oc(=O)cc(CCl)c2c1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PON1 P27169 3/20 0.66
DYRK1A Q13627 1/20 0.66
KMT2A Q03164 4/20 0.59
NR2E3 Q9Y5X4 1/20 0.59
KDM4E B2RXH2 2/20 0.58
HSD17B10 Q99714 1/20 0.58
MCL1 Q07820 2/20 0.57
TSHR P16473 1/20 0.56
MAPK1 P28482 1/20 0.54
RAB9A P51151 1/20 0.54
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PRKDC P78527 1/20 0.48
MAPT P10636 2/20 0.47
HTT P42858 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5969658 0.87 KMT2A (0.59) PON1DYRK1AKMT2AKDM4EHSD17B10
SCHEMBL13483549 0.81 HSD17B3 (0.60) DYRK1AKMT2ANR2E3KDM4EHSD17B10
SCHEMBL15245387 0.80 MCL1 (0.66) PON1DYRK1AKMT2AKDM4EMCL1
SCHEMBL24938765 0.80 DYRK1A (1.00) PON1DYRK1AKMT2AKDM4EHSD17B10
SCHEMBL15245384 0.80 KMT2A (0.62) PON1DYRK1AKMT2ANR2E3KDM4E
SCHEMBL19354020 0.78 KMT2A (0.54) PON1DYRK1AKMT2ANR2E3KDM4E
SCHEMBL5456535 0.77 ALDH1A1 (0.51) KMT2ANR2E3KDM4EHSD17B10TSHR
SCHEMBL1209429 0.77 PON1 (0.58) PON1DYRK1AKMT2AKDM4EHSD17B10
SCHEMBL30636721 0.77 ALDH1A1 (0.64) KDM4EHSD17B10MCL1TSHRALDH1A1
SCHEMBL67818 0.77 ALDH1A1 (0.64) KDM4EHSD17B10MCL1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME MEDSHINE DISCOVERY INC. (CN) 2023-05-25 US disclosed
US-8742132-B2 Indolylmaleimide derivatives processes for their production and pharmaceutical compositions NOVARTIS AG (CH) 2014-06-03 US disclosed
US-8742132-B2 Indolylmaleimide derivatives processes for their production and pharmaceutical compositions NOVARTIS AG (CH) 2014-06-03 US disclosed
US-8742132-B2 Indolylmaleimide derivatives processes for their production and pharmaceutical compositions NOVARTIS AG (CH) 2014-06-03 US disclosed
EP-2094689-B1 INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-04-03 EP disclosed
EP-2094689-B1 INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-04-03 EP disclosed
US-20120219593-A1 INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS NOVARTIS AG 2012-08-30 US disclosed
US-20120219593-A1 INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS NOVARTIS AG 2012-08-30 US disclosed
US-20120219593-A1 INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS NOVARTIS AG 2012-08-30 US disclosed
US-8193236-B2 Indolylmaleimide derivatives processes for their production and pharmaceutical compositions NOVARTIS AG (CH) 2012-06-05 US disclosed
CN-101558062-A Indolylmaleimide derivatives as kinase inhibitors NOVARTIS AG (CH) 2009-10-14 CN disclosed
US-20090233232-A1 PHOTOSENSITIVE COMPOUND, PHOTOSENSITIVE COMPOSITION, RESIST PATTERN FORMING METHOD, AND DEVICE PRODUCTION PROCESS CANON KABUSHIKI KAISHA (JP) 2009-09-17 US disclosed
EP-2094689-A2 INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS Novartis AG (CH) 2009-09-02 EP disclosed
CN-101256358-A Photosensitive compound, photosensitive composition, resist pattern forming method, and device production process CANON KK (JP) 2008-09-03 CN disclosed
EP-1956430-A1 Photosensitive compound, photosensitive composition, resist pattern forming method, and device production process Canon Kabushiki Kaisha (JP) 2008-08-13 EP disclosed
US-20080187864-A1 PHOTOSENSITIVE COMPOUND, PHOTOSENSITIVE COMPOSITION, RESIST PATTERN FORMING METHOD, AND DEVICE PRODUCTION PROCESS CANON KABUSHIKI KAISHA (JP) 2008-08-07 US disclosed
WO-2008074752-A2 INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2008-06-26 WO disclosed
WO-2008074752-A2 INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2008-06-26 WO disclosed
US-20030035917-A1 Image making medium HYMAN SYDNEY (US) 2003-02-20 US disclosed
US-4634701-A Furan derivatives having anti-ulcer activity AUSONIA FARMACEUTICI S.R.L. (IT) 1987-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME PSMA6, PSMC1, PSMA1 PON1 593/4885DYRK1A 3072/4885KMT2A 1544/4885
US-20090233232-A1 PHOTOSENSITIVE COMPOUND, PHOTOSENSITIVE COMPOSITION, RESIST PATTERN FORMING METHOD, AND DEVICE PRODUCTION PROCESS FRG1, PAH, RER1 PON1 3488/4885DYRK1A 4233/4885KMT2A 1323/4885
US-20080187864-A1 PHOTOSENSITIVE COMPOUND, PHOTOSENSITIVE COMPOSITION, RESIST PATTERN FORMING METHOD, AND DEVICE PRODUCTION PROCESS FRG1, PAH, RER1 PON1 3488/4885DYRK1A 4233/4885KMT2A 1323/4885
US-20120219593-A1 INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS RB1, INMT, IDH3A PON1 3503/4885DYRK1A 1548/4885KMT2A 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.